Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of OPC 1 in parenchymal delivery injection for Spinal Cord Injuries

Next Previous
X
Search
Trial Profile

A clinical study of OPC 1 in parenchymal delivery injection for Spinal Cord Injuries

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OPC 1 (Primary)
  • Indications Spinal cord injuries
  • Focus Therapeutic Use
  • Acronyms DOSED

    • Most Recent Events

    • 13 Feb 2024 According to Lineage Cell Therapeutics media release, Initial site opening is expected to occur in the second quarter of 2024, following customary trial preparations and submission in the first quarter of a grant application to the California Institute for Regenerative Medicine (CIRM) for potential partial financial support of the DOSED clinical study.
    • 13 Feb 2024 According to Lineage Cell Therapeutics media release, company announced the clearance, by the U.S. Food and Drug Administration (FDA), of its Investigational New Drug amendment (INDa) for OPC1. Pursuant to the INDa, Lineage has initiated activities to open its first clinical site in this study.
    • 11 Aug 2023 According to a Lineage Cell Therapeutics media release, IND amendment preparation underway, with plans to submit to FDA in Q4.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top